Drug Trial Radar · NCT07266116
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 26, 2025
Primary completion
Feb 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the safety and preliminary efficacy, pharmacokinetic (PK) characteristics, immunogenicity, and pharmacodynamic (PD) of TQB2934 for injection in subjects with systemic light chain amyloidosis, and to determine the recommended Phase II dose (RP2D). The Phase II plan involves enrolling 49 subjects, aiming to demonstrate that in adult subjects with relapsed/refractory systemic light chain amyloidosis who have previously received treatment with daratumumab and bortezomib, TQB2934 for injection significantly improves the hematological complete response (CR) rate compared to historical controls. The primary endpoint is the optimal hematological CR rate.
Conditions
- Systemic Light Chain Amyloidosis
Interventions
TQB2934 injectionDrug
TQB2934 for injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3). One end binds to the CD3 receptor on the surface of T cells, while the other end binds to BCMA, recruiting T cells to BCMA-positive cells. This can activate T cells, which then release granzyme, perforin, and other enzymes to kill BCMA-positive malignant plasma cells, thereby reducing the level of monoclonal immunoglobulin light chains in the body and delaying further organ damage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of subjects with adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs)Time frame: Baseline to the end of the study, about 4 years
- The best hematological response evaluated by the Independent Review Committee (IRC) is complete remission (CR)Time frame: Baseline to CR,about 1.5 years
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Southwest Hospital, Third Military Medical University (Army Medical University)
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
Guangzhou First Municipal People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Peking University ShenZhen Hospital
Shenzhen, Guangdong, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Not yet recruiting
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
Anyang People's Hospital
Anyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
The second Affiliated hospital of dalian medical university
Dalian, Liaoning, China · Not yet recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, China · Not yet recruiting
Qingdao municipal hosptial (group)
Qingdao, Shandong, China · Not yet recruiting
Renji Hospital Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
Chinese Academy of Medical Sciences Hematology Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.